As primary and acquired resistance to checkpoint inhibitor immunotherapies remains a significant barrier to long-term remission for the majority of patients, further validation of CGB7 as a biomarker and characterization of the mechanism by which CGB7 suppresses the anti-cancer effects of ICIs may help us predict patient response, inform treatment, and perhaps even identify CGB7 as a potential therapeutic target. Here, CGB7 is linked to cancer.